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a b s t r a c t
Andrographolide (AG) is the characteristic constituent of Andrographis paniculata, of the Acanthaceae
family. This plant is a well-known Asian medicinal plant that is widely used in India, China, and
Thailand. A monograph of Herba Andrographidis (Chuan Xin Lian) is included in the Pharmacopoeia of
the People’s Republic of China, which reports that this decoction can ‘‘remove heat, counteract toxicity,
and reduce swellings.” The numerous potential activities of AG range from anti-inflammatory to anti-
diabetic action, from neuroprotection to antitumor activity, and from hepatoprotective to anti-obesity
properties. However, AG has low bioavailability and poor water solubility, which can limit its distribution
and accumulation in the body after administration. In addition, AG is not stable in gastrointestinal alka-
line and acidic environments, and has been reported to have a very short half-life. Among the diverse
strategies that have been adopted to increase AG water solubility and permeability, the technological
approach is the most useful way to develop appropriate delivery systems. This review reports on pub-
lished studies related to microparticles (MPs) and nanoparticles (NPs) loaded with AG. MPs based on
polylactic-glycolic acid (PLGA), alginic acid, and glucan derivatives have been developed for parenteral
oral and pulmonary administration, respectively. NPs include vesicles (both liposomes and niosomes);
polymeric NPs (based on polyvinyl alcohol, polymerized phenylboronic acid, PLGA, human serum albu-
min, poly ethylcyanoacrylate, and polymeric micelles); solid lipid NPs; microemulsions and nanoemul-
sions; gold NPs; nanocrystals; and nanosuspensions. Improved bioavailability, target-tissue
distribution, and efficacy of AG loaded in the described drug delivery systems have been reported.
! 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and
Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Andrographis paniculata (Burm.f.) Nees is a well-known Asian
medicinal plant of the Acanthaceae family (Fig. 1). It is called Fa-
Tha-Lai-Jone in Thailand [1]; Kalmegh in Ayurvedic medicine; and
Chiretta or ‘‘King of Bitters” in India, China, and Thailand [2,3]. A
monograph of Herba Andrographidis (Chuan Xin Lian) is included
in the Pharmacopoeia of the People’s Republic of China, which
reports that this decoction acts to ‘‘remove heat, counteract toxic-
ity, and reduce swellings” [4]. Traditional indications for the use of
this decoction include effects in the upper respiratory tract, such as
the common cold, bronchitis, sinusitis, pharyngotonsillitis, whoop-
ing cough, pneumonia, and otitis media. In addition, activity
against diarrhea, enteritis, lower urinary infections, dermatitis,
and tuberculosis has traditionally been reported [4–6].
Activity against the common cold, pharyngotonsillitis, uncom-
plicated sinusitis, bronchitis, acute diarrhea, and urinary infections
is also supported by clinical data reported in the World Health
Organization (WHO) monograph on Herba Andrographidis [7].
The main active constituents of Herba Andrographidis are
bicyclic diterpenes with a c-lactone moiety, which principally
include andrographolide (AG, Fig. 2) and its analogs,
14-deoxyandrographolide, neoandrographolide, and 14-deoxy-11
-12-didehydroandrographolide [8]. In addition to the numerous
potential activities of AG, which range from anti-inflammatory to
anti-diabetic action, from neuroprotection to antitumor activity,
and from hepatoprotective to anti-obesity properties [9], AG
has poor water solubility, which limits its distribution and
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accumulation in the body after administration. In addition, AG is
unstable in gastrointestinal media and possesses a very limited
half-life (circa (ca.) 2 h) [10].
2. Microparticles and nanoparticles loaded with AG
AG is a very promising natural product with various potential
therapeutic benefits; however, it has not reached its milestone
therapeutic potential due to its low bioavailability when adminis-
tered in conventional dosage forms. The development of suitable
delivery systems for AG is an urgent issue in the development of
efficacious therapeutic approaches for this compound. Among the
diverse strategies that have been adopted to increase AG water sol-
ubility and permeability, the technological approach is the most
useful way to develop suitable delivery systems. A very simple
approach to improve the solubility of a molecule is to modify the
particle size through micronization and nanonization techniques,
which can enhance the total surface area with a consequent
improvement of the dissolution behavior. Microparticles (MPs)—
solids or small droplets of liquids enclosed in natural or synthetic
polymers of variable thickness and permeability—are frequently
used in this endeavor in order to obtain a controlled release of
the encapsulated drug. Both organic and inorganic nanoplatforms
(Fig. 3) can also increase solubility to an extraordinary degree,
and can enhance photostability, chemical stability, bioavailability,
and tissue distribution. These nanocarriers can overcome
multidrug-resistance phenomena and cross biological barriers,
including the blood–brain barrier. Organic nanoparticles (NPs)
include polymeric and lipid NPs. Among lipid NPs, vesicles,
microemulsions (MEs), nanoemulsions (NEs), and solid lipid NPs
(SLNs) are the most widely investigated. Finally, the simple use
of nanopowders ranging in size from 10 to 1000 nm are an alterna-
tive way to enhance the solubility of AG, principally due to the
increased dissolution properties that result from the greater sur-
face areas in comparison with similar masses of larger scale mate-
rials. For these formulations, which are mainly suitable for oral or
parenteral administration, surfactants or hydrophilic polymers
should be added during milling for surface stabilization, in order
to inhibit the formation of aggregates.
2.1. Microparticles
MPs include microspheres and microcapsules. A microcapsule is
characterized by an internal core and an external shell. The inter-
nal core can be liquid (i.e., oil or water) or solid, and typically con-
tains the active ingredient, while the shell is usually a polymer or
wax. A microsphere is a solid matrix particle; the active ingredient
is usually dissolved or melted in the matrix.
A study investigated the development of sustained-release
microspheres based on the copolymer obtained from lactic and
glycolic acid—polylactic-glycolic acid (PLGA)—loaded with AG.
PLGA microspheres were prepared by an emulsion solvent evapo-
ration method. The formulation was optimized using response sur-
face methodology, which was used to identify the optimum levels
of the process variables, which had significant effects on particle
size and entrapment efficiency. The study focused on the develop-
ment of spherical microspheres with an average particle size of
53.18 ± 2.11 lm. The entrapment efficiency (EE%) was
75.79 ± 3.02%, while the drug loading was 47.06 ± 2.18%. The
release kinetics followed the Korsmeyer-Peppas model, with a
low initial burst followed by a successive prolonged release (up
to 9 days). After intramuscular administration of the MPs, AG
plasma concentrations were found to be moderately high over a
period of one week [11].
It is generally accepted that high doses of AG provide hepatic
protection; however, due to the extremely bitter properties of
AG, sickness and nausea can frequently occur. To address this issue,
bitterless MPs prepared with sodium alginate and calcium ions
were developed using various AG:alginate ratios (i.e., 1:2, 1:1,
and 2:1). The release kinetics of the developed MPs fitted well with
the Korsmeyer-Peppas equation: The MPs released at acidic pH
(1.2 or 4.0) with ca. 15% release for up to 4 h; a complete release
of the remaining AG then occurred at pH 7.4. The developed MPs
were very useful for the oral delivery of AG and had a good EE%,
with 86% release [12]. In a further study, the same authors investi-
gated the mechanism of gelation for the entrapment of AG. AG sta-
bility was obtained in the cross-linked MPs [13]. A micronized
formulation for a dry powder inhaler (DPI) was also developed
using a natural polysaccharide, scleroglucan. The MPs displayed a
mean aerodynamic diameter of 3.37 ± 0.47 mm. The in vivo studies
exhibited a suitable AG lung deposition, and no inflammation or
toxicity was found after 24 h. Moreover, the formulation demon-
strated improved activity in pulmonary arterial hypertension [14].
2.2. Nanoparticles
2.2.1. Polymeric nanoparticles
Polymeric nanoparticles (PNPs, Fig. 3) are the most widespread
delivery systems. These include nanospheres and nanocapsules.
Nanospheres are matrix systems in which the drug is homoge-
neously distributed, while in nanocapsules, the drug is contained
in a core, which is walled in by an outer shell. Polymers used for
the preparation of PNPs are classified as synthetic or natural (i.e.,
Fig. 1. Andrographis paniculata (Burm.f.) Nees, (Acanthaceae).
Fig. 2. Andrographolide (AG), the main characteristic diterpenoid in Andrographis
paniculata.
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biopolymers), and are commonly classified as biodegradable or
non-biodegradable as well. Biodegradation of a polymer involves
the cleavage of hydrolytic or enzymatic bonds in the polymer, lead-
ing to polymer erosion. Most naturally occurring polymers
undergo enzymatic degradation and are thus the first biodegrad-
able biomaterials used in pharmaceutical technology. Natural
polymers include proteins (e.g., albumin, gelatin, soy protein
hydrolysate, and casein) and polysaccharides (pectin, cellulose,
starch, gum arabic, carrageenan, alginate, xanthan gum, gellan
gum, and chitosan) [15].
Roy et al. [16] developed PLGA PNPs loaded with AG and coated
with chitosan for antitumor therapy. The PNPs were nontoxic and
increased the anticancer activity by threefold in the MCF-7 cell line
and in vivo studies using Ehrlich ascites carcinoma (EAC) cells, in
comparison with unformulated AG. The anticancer activity of AG
loaded in other PNPs was tested for specific targets. Kim et al.
[17] formulated water-soluble PNPs for systemic administration,
using a polymer obtained from phenylboronic acid. This nanocar-
rier displayed exceptional targeting properties both in vitro and
in vivo, and resulted in a significant decrease of in vivo tumor
growth. Roy et al. [18] prepared AG loaded in PLGA PNPs (50:50),
which were stabilized with polyvinyl alcohol (PVA). The study
focused on AG delivery into macrophage cells infected with leish-
manial parasite. The PNP average size was 173 nm, with a surface
charge of !34.8 mV. Activity on the infested macrophages was sig-
nificant in the case of PNPs containing 4% PVA (IC50 of
34 lmol"L!1), which is a one-quarter dose of pure AG (IC50 of
160 lmol"L!1). The same authors recently prepared PNPs with hep-
atoprotective activity for use in hepatotoxic conditions. Cationic
modified PLGA PNPs loaded with AG were developed, and showed
superior dissolution behavior in comparison with pure AG and
favorable cytokine regulation in the hepatic tissues, leading to a
rapid recovery of mouse liver [19]. Moreover, in 2017, Das et al.
[20] explored the effectiveness of AG encapsulated in PLGA PNPs
against liver damage in mice induced by arsenic. The PNPs had
an average diameter of 65.8 nm and the EE% was 64%. The NPs
increased the level of reduced glutathione and antioxidant
enzymes, including superoxide dismutase and catalase. The pro-
tective efficiency of AG loaded in PNPs was about five times greater
in comparison with unformulated AG. NP administration improved
the liver tissue architecture, suggesting a beneficial effect against
arsenic-induced liver toxicity. AG has also been reported to amelio-
rate neurodegenerative disorders. To overcome its low brain distri-
bution, Guccione et al. [10] loaded AG into NPs made of albumin
(ANPs) and ethylcyanoacrylate (ENPs). The ability of both NPs to
permeate the blood–brain barrier (BBB) was investigated using
an in vitro BBB model, hCMEC/D3. Although AG was unable to cross
the BBB model to any significant degree, the ANPs improved the
permeation of AG by twofold. In addition, the integrity of the cell
layer was maintained. In contrast, while ENPs increased the cross
properties of AG, the BBB was temporarily disordered. Another
nanovector that was tested involved pH-sensitive PNPs based on
a cationic poly methacrylate copolymer (Eudragit" EPO). The opti-
mized formulation consisted of Pluronic" F-68 (0.6% w/v) and
Eudragit" EPO (0.45% w/v). It had a very high EE% (93.8 ± 0.67%),
homogeneous particle size (255 ± 9 nm), and good superficial
charge values (29.3 ± 3.4 mV). The in vivo absorption of AG and
of AG loaded in the NPs was studied at a dose of 10 mg"kg!1 in
male Wistar albino rats. The AG loaded in PNPs caused a tremen-
dous increase in area under the curve (AUC) (ca. 2.2 fold) and Cmax
(3.2 fold) in comparison with unformulated AG. In addition, the
relative bioavailability increased by 121.53% (p < 0.05) in compar-
ison with pure AG. Other parameters were favorably affected by
the loading of AG in NPs: A shorter Tmax (4.0 fold) and a reduction
in Cl/F (2.2 fold) were observed [21].
2.2.2. Polymeric micelles
Polymericmicelles (Fig. 3) are self-assembling colloids of amphi-
philic polymers, which can spontaneously aggregate in a particular
solvent (generally water). AG was entrapped in a micellar formula-
tion based on an amphiphilic triblock copolymer of D,L-lactic acid,
glycolic acid, and ethylene glycol, poly(lactide-co-glycolide)-bloc
k-poly(ethylene glycol)-block-poly(lactide-co-glycolide) (PLGA-
PEG-PLGA), and then evaluated for bioavailability in vivo and for
in vitro cytotoxicity. Cellular uptake and cytotoxicity, including cell
cycle arrest, proliferation inhibition, and pro-apoptosis effects were
Fig. 3. Nanocarriers have been developed to improve the bioavailability, target-tissue distribution, and efficacy of AG, the ‘‘king of bitters.” NPs: nanoparticles; PNPs:
polymeric nanoparticles; SLNs: solid lipid NPs; MEs: microemulsions; NEs: nanoemulsions.
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tested against human breast cancerMAD-MD-231 cells. The loading
efficiency of the micelles was about 92%, and the particle size was
124.3 ± 6.4 nm. The micelles exhibited a higher inhibition of prolif-
eration when compared with the unformulated AG. The highest
effectiveness of cellular uptake and intracellular transport, pro-
apoptotic properties, and cell cycle arrest at the G2/M phase were
found in MAD-MD-231 cells using the micelles. Pharmacokinetics
studies were carried out in rats, and both the mean residence time
and plasma AUC0–1 were found to increase by almost threefold in
comparison with unformulated AG [22].
In a further study, a series of copolymers obtained from ethy-
lene glycol and D,L-lactic acid (mPEG-PLA) with various ratios of
hydrophilic to hydrophobic portions was synthetized to encapsu-
late AG. The micelles had a size of 92.84 ± 5.63 nm, a high EE% of
91.00% ± 11.53%, and a loading capacity of 32.14% ± 3.02% (w/w).
mPEG-PLA loaded with AGwas found to have good stability against
salt dissociation, protein adsorption, and anion substitution. The
solubility of AG and a derivative of AG (14-deoxy-11,12-didehy
droandrographolide) in micelles increased by 4.51 times and 2.12
times in water in comparison with unformulated AG. mPEG-PLA
loaded with AG showed the same release profile in a different dis-
solution medium. Cytotoxicity testing in vitro demonstrated that
AG loaded in mPEG-PLA exhibited higher cell viability inhibition
in mouse breast cancer 4T-1 than free AG [23].
2.2.3. Vesicles
Vesicles (Fig. 3) are colloidal vectors formed by bilayers, which
can load hydrophilic and hydrophobic compounds. Liposomes are
principally constituted of natural phospholipids and cholesterol,
while niosomes are nonionic surfactant-based vesicles [24].
A very recent study by Kang et al. [25] reported on liposomal co-
delivery of AG and doxorubicin to inhibit breast cancer growth and
metastasis. The liposome was prepared with a cell-penetrating
peptide, which was able to inhibit the in vitro proliferation of
4T1 cells. Two distinctive tests were done: a wound-healing assay
and a trans well invasion assay. The liposome was found to
enhance AG accumulation in tumors and to result in high intra-
tumor penetration in a tumor mouse model of breast. A synergistic
effect of doxorubicin and AG was found. In another study, AG-
loaded niosomes were prepared. The niosomes improved the tissue
distribution and bioavailability of AG in mice. In particular, AG-
loaded niosomes accumulated in the liver much more than the free
drug. In vitro studies on anti-hepatocellular carcinoma (HCC) effi-
cacy in HepG2 cells disclosed no significant differences between
the free drug and AG-loaded niosomes [26]. In a further study,
loading AG in a natural soya-phosphatidylcholine mixture was
found to enhance the absorption and hepatoprotective activity of
AG in comparison with unformulated AG. The study proved the
hepatoprotective potential of AG using a rat model of hepatotoxi-
city induced by carbon tetrachloride. The results showed signifi-
cantly increased absorption, bioavailability, and hepatoprotective
potential of AG loaded in vesicles when compared with the unfor-
mulated drug. The effects of AG-loaded vesicles were comparable
to those of silymarin, which is used as a standard drug [27]. Maiti
et al. [28] obtained similar results in a study using the same formu-
lation in rats. The formulation had an improved bioavailability and
a better hepatoprotective activity than unformulated AG. The for-
mulation was very helpful in solving the problem of rapid clear-
ance and low elimination caused by the short half-life of AG. In
an additional study, Sinha et al. [29] reported the capacity of AG
encapsulated in liposome and decorated with mannosyl or fucosyl
(as active targeting for macrophages) to reduce hepatic and renal
toxicity. Furthermore, a decrease was observed in the parasitic
burden of experimental leishmaniosis in a hamster model and in
the splenic tissue histological architecture when compared with
treatment with unformulated AG or conventional AG-loaded lipo-
somes. In a further study, Li et al. [30] developed AG-loaded liposo-
mal dry powder inhalers (LDPIs) for pulmonary delivery for the
treatment of pneumonia induced by Staphylococcus aureus. The
AG-loaded liposomes were freeze-dried to formulate LDPIs, and
were found to be suitable for pulmonary delivery. A stronger
in vivo anti-S. aureus pneumonic effect of the formulation was
found at a tenfold dose, in comparison with unformulated AG or
penicillin. The LDPIs significantly reduced the tumor necrosis fac-
tor a (TNF-a) and interleukin 1 (IL-1) pro-inflammatory cytokines.
Phosphorylation of IjB-a in the nuclear factor-jB pathway was
also inhibited to an extraordinary degree.
Piazzini et al. [31] developed liposomes for the central nervous
system (CNS) delivery of AG by adding Tween 80 alone or in combi-
nationwith didecyldimethylammoniumbromide in order tomodify
the surface of the vesicles. The ability of liposomes to increase the
permeability of AG was evaluated by a parallel artificial membrane
permeability assay (PAMPA) and hCMEC/D3 cells. The size of the
liposomes ranged from 96.4 ± 9.5 nm to 82.1 ± 9.3 nm, and the EE%
ranged from 44.7% ± 3.2% to 47.5% ± 3.3%. The liposomes showed
excellent stability as suspensions or freeze-dried products. PAMPA
and hCMEC/D3 transport studies revealed that all the developed
liposomes increased the permeability of AG, in comparisonwith free
AG. No alterations in cell viability were found. The main uptake
mechanism was caveolae-mediated endocytosis, and the increased
cellular internalization of the formulations was related to the posi-
tive charge [31].
2.2.4. Solid lipid nanoparticles
SLNs (Fig. 3) are formulated with physiological lipids, which are
dispersed in water or in an aqueous surfactant solution. SLNs are
typically spherical, with an average diameter between 10 and
1000 nm. The solid lipid core is stabilized by surfactants (emulsi-
fiers) and formulated using fatty acids, monoglycerides, diglyc-
erides, triglycerides, steroids, and waxes. All classes of
emulsifiers can be used to stabilize the lipid dispersion, thus pre-
venting particle agglomeration more efficiently [15].
AG encapsulated into SLNs was found to enhance antitumor
activity in Balb/c mice because of an enhancement of bioavailabil-
ity due to the improvement of the AUC and Cmax of AG in compar-
ison with unformulated AG. A sustained-release pattern of AG-
loaded SLNs was indicated by an increased value of Tmax [32].
AG-loaded SLNs with an average diameter of 286.1 nm and a
zeta potential of !20.8 mV were developed to improve AG
bioavailability. The AG EE% was 91.00%, while the drug loading
was 3.49%. Both the bioavailability and anti-hyperlipidemic effi-
cacy of AG-loaded SLNs were improved by increasing the stability
and solubility of AG in the gastro-enteric tract. The bioavailability
of AG loaded in SLN was increased to 241% in comparison with
unformulated AG [33].
AG-loaded SLNs were formulated using Compritol 888 ATO and
Brij 78. The EE% was 92%. The SLNs showed exceptional physical
and chemical stability at 4 #C and 25 #C after storage for one
month. The SLNs were also stable when dispersed in human serum
albumin and plasma. The in vitro release of AG-loaded SLNs at
physiological pH was prolonged and sustained. The SLNs’ ability
to cross the BBB was evaluated in vitro by the PAMPA test and
hCMEC/D3 cells in order to predict the passive transcellular perme-
ability. The SLNs improved the permeability of AG in comparison
with free AG, and the data from the two tests were comparable.
Intravenously administered fluorescent SLNs were detected in
brain parenchyma outside of the vessel, thus establishing their
ability to cross the BBB [34].
2.2.5. Nanoemulsions and microemulsions
Both NEs and MEs (Fig. 3) are nanoscale emulsions character-
ized by high stability and transparency. However, the terms
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‘‘ME” and ‘‘NE” are not interchangeable; an ME is an isotropic liq-
uid mixture that forms spontaneously and is thermodynamically
stable, whereas an NE is a nanoscale dispersion that is obtained
by means of mechanical force and is only kinetically stable. The
two phases of NEs and MEs may be water-continuous or oil-
continuous. In addition, MEs can present bicontinuous systems
(also called sponge-like systems) [15,35]. An AG-loaded NE was
formulated in order to improve oral bioavailability and protective
action against inflammatory bowel disease. The AG-loaded NE
was prepared with water, ethanol, a-tocopherol, and Cremophor
EL. The optimized AG-loaded NE was stable at 4 #C and 25 #C for
three months, and had a droplet size of (122 ± 11) nm and a viscos-
ity of 28 centipoise. An ex vivo test using an everted rat gut sac
indicated that the jejunum was the optimal site for AG loaded in
the NE. AG activity was 8.21 and 1.40 times higher than the values
obtained with AG suspension and AG ethanol solution, respec-
tively. The pharmacokinetic results showed a relative bioavailabil-
ity of 594.3% when the AG-loaded NE was compared with an AG
suspension. In addition, the ulcer index and histological damage
score of indomethacin-induced intestinal lesions in mice were sig-
nificantly reduced by pretreatment with AG-loaded NE [36].
An oil in water (O/W) ME loaded with AG was developed using
isopropyl myristate, Tween 80, ethanol, and water. The mean dro-
plet size was 15.9 nm, and the solubility of AG was 8.02 mg/mL.
The formulation was stable, with a higher anti-inflammatory effect
and bioavailability than AG tablets; it displayed no acute oral tox-
icity [37].
A special NE loaded with AG was prepared using layer-by-layer
technology via electrostatic deposition of chitosan over alginate-
encrusted O/W NE by means of ultra-sonication. The best stability
was obtained after 20 min of sonication. The particle size of the
multi-layered NE was measured to be within the range of 90.8–
167.8 nm, with a zeta potential between 22.9 and 31.01 mV. The
NE showed a strategic release pattern when assessed in vitro in
various simulated biological fluids. It showed significant modula-
tion in a liver function test (ALT, ALP, AST, TBIL, DBIL, and liver
glycogen) and serum cytokines (IL-b TNF-a, IL-10, and IL-6) when
assessed in vivo in galactosamine-lipopolysaccharide-intoxicated
mice, thus exhibiting significantly improved hepatoprotection
[38].
2.2.6. Gold nanoparticles
Functionalized gold NPs (Fig. 3) are smart vectors for biomed-
ical applications that can control geometrical and optical proper-
ties. Their large surface can be coated with diverse molecules
(i.e., targeting agents, drugs, and anti-fouling polymers), making
them versatile carriers. In particular, the targeted delivery of
drugs is one of the most encouraging medicinal uses of gold
NPs [39].
Engineered gold NPs loaded with AG, with a spherical geometry
of 14 nm and a polydispersion index (PDI) value of 0.137, were
developed. They exhibited resilient anti-leishmanial activity,
against both wild-type (IC50 of 19 ± 1.7 mmol"L!1) and sodium sti-
bogluconate (IC50 of 55 ± 7.3 mmol"L!1)/paromomycin (IC50 of
41 ± 6 mmol"L!1)-resistant strains. Complete macrophage uptake
of AG gold NPs occurred within 2 h of exposure, and the cytotoxi-
city was significantly lower than that of amphotericin-B [40].
2.2.7. Nanocrystals and nanosuspensions
Ma et al. [41] designed a fast-dissolving nanocrystal-based solid
dispersion to enhance thedissolutionof AG. Thenanodispersionwas
formulated using various ratios of hydroxypropyl methylcellulose
(HPMC) and three super disintegrant excipients: sodium car-
boxymethyl starch, mannitol, and lactose. The dispersion with the
highest concentration ofHPMCexhibited themost rapidAGdissolu-
tion properties, probably due to the enhanced wettability. The per-
formance of the super-disintegrants at a level of 20%, in
combination with 25% HPMC, was tested. The formulation
developed with 15% sodium carboxymethyl starch, 15% HPMC, and
10% lactose improved the dissolution (drug loading was up to
67.83 ± 1.26%). The in vivo pharmacokinetics studies revealed a sig-
nificantly enhanced bioavailability of AG in comparisonwith unfor-
mulated AG. A nanodispersion was prepared and its performance
tested. The dissolution rate (85.87%),Cmax (299.32 ± 78.54 ng"mL!1),
and AUC0–1 (4440.55 ± 764.13 mg"h"L!1) of the AG nanodispersion
were significantly higher (p < 0.05) in comparison with crude AG.
The AUC was three times higher [42]. AG nanosuspensions contain-
ing glycyrrhizin had a mean particle size of 487 nm and exhibited
excellent performance in comparison with those obtained with tre-
halose. The dissolution percentage of these AG nanosuspensions
(99.87%) was significantly increased in comparison with that of
unformulated AG (42.35%) [43].
In another study, an AG nanosuspension was prepared using D-
a-tocopheryl polyethylene glycol 1000 succinate (TPGS, a surfac-
tant that inhibits P-glycoprotein function) and sodium lauryl sul-
fate. The mean particle size was 244.6 ± 3.0 nm and the re-
dispersibility index was 113 ± 1.14% (n = 3). Increased dissolution
behavior was found; in addition, a Caco-2 cell monolayer test
revealed that the membrane permeability (Papp) of AG in the
nanosuspension was significantly higher than those of unformu-
lated AG or AG nanosuspensions without TPGS (p < 0.01). Further-
more, the nanosuspension containing TPGS exhibited significantly
higher Cmax and AUC0–t (p < 0.01). A study using carrageenan-
induced paw edema demonstrated that an AG nanosuspension
containing TPGS was more effective and produced a greater
increase in the serum levels of NO, IL-1, and TNF-a (p < 0.01) and
in superoxide dismutase (SOD) activity (p < 0.05) in comparison
with unformulated AG [44].
Nanosuspensions were formulated with 3% AG, 5% poloxamer
188, 0.1% sodium tauroursodeoxy cholate, or 0.05% sodium deoxy-
cholate, with 0.4 mm zirconium oxide pearls. These nanosuspen-
sions showed a hexagonal morphology and a particle size of
300 nm, but no change in the crystalline habitus. A significant
increase in saturation solubility was found, resulting in complete
release within 0.25 h. The lyophilized formulation using mannitol
(5%) as a cryoprotectant had respectable physical and chemical sta-
bility during the six-month storage period. Pharmacokinetic and
tissue distribution studies revealed that the AG was mainly dis-
tributed in the liver and was rapidly eliminated from the blood
[45].
3. Conclusions
Microcarriers and nanocarriers are a tremendously important
field of research in bioactive constituents, which include natural
products and herbal extracts. The use of these technologies has
already had a significant impact on many areas of medicine by
allowing appropriate therapeutic treatments of certain essential
drugs (principally antitumor and antiparasitic drugs). In addition
to its numerous potential activities, AG, which is the characteristic
constituent of Andrographis paniculata (Burm.f.) Nees, has a low
bioavailability, limited biodistribution and localization, lack of sta-
bility in gastrointestinal environments, and very short biological
half-life. Remarkable results have been obtained in improving AG
bioavailability, target-tissue distribution, and efficacy using
micro- and nano-formulations based on AG; these achievements
represent a decisive step toward establishing a key role for AG in
modern clinical treatment.
In comparing the formulations reported in this review, it can
generally be stated that nanocarriers have certain advantages over
micro-delivery systems: They are more stable, provide more
surface area, and are able to overcome anatomical barriers and
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physiological clearance mechanisms. Therefore, with nanocarriers,
AG activity becomes enhanced, more detectable, and prolonged.
Each nanoparticle has its own advantages, disadvantages, and
characteristics.
The use of nanopowders is the simplest and most affordable
technique to enhance AG solubility. This approach is typically
carrier-free, and is the most suitable technology for compounds
with a Papp value <10!5, a high melting point, and high doses, as
in the case for many natural products. The advantages of this
approach include improved absorption after oral, mucosal, and
parenteral administration; the ability to control the rate and extent
of drug absorption; low cost; and easy scale-up. However, the lim-
itations of this approach are numerous, because these nano-
formulations are not able to enhance photostability or chemical
stability, overcome multidrug-resistance phenomena, or impart
passive and active targeting.
Both lipid and polymeric NPs can overcome all the limitations of
nanopowders; in particular, polymeric NPs can address biocompat-
ibility and low biodegradability and their resulting safety issues,
especially after long-term administration. A main limitation of
SLNs is their low loading capacity and leakage during storage. This
limitation can be overcome by using the new improved generation
of lipid nanocarriers—the so-called nanostructured lipid carriers—
which have a higher loading capacity and somewhat less water
in the dispersion due to more complex lipid mixtures and the pres-
ence of both solid (fat) and liquid (oil) lipids at ambient tempera-
ture within the hydrophobic core. The use of these nanovectors for
AG has not been reported in the literature; however, they could be
a suitable tool to further improve the therapeutic use of AG.
Vesicles are very versatile nanocarriers and offer many advan-
tages: Both hydrophilic and hydrophobic drugs can easily be
encapsulated in vesicles due to the presence of the hydrophilic
compartment and lipophilic palisade, thus increasing their
bioavailability, delaying their metabolism, and prolonging their
circulation lifetime. In addition, both passive and active targeting
can be achieved using vesicles. The disadvantages and limitations
of vesicles include their leaky nature, which leads to premature
drug release; their poor encapsulation efficiency; the fact that they
are quite expensive; and their low utility after oral administration.
Both MEs and NEs are interesting nanovectors because they are
able to load high doses of a drug (up to 20% w/w) and present many
advantages over other nanosystems. They can be administered by
all routes, control the rate and extent of drug absorption, increase
solubility and bioavailability, enhance photostability and chemical
stability, and overcome multidrug-resistance phenomena. In addi-
tion, MEs and NEs are superior over nanocarriers due to their low
cost and easy scale-up.
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